Reata Pharmaceuticals Inc - Class A
RETA
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.57B
Close$
$188.61
9.4% upside
Current Fair Value
9.4% upsideUndervalued by 9.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.57 Billion |
|---|---|
| Enterprise Value | $6.77 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.59 |
| Beta | 1.42 |
| Outstanding Shares | 41,506,900 |
Return
| Return on Equity | -94.25% |
|---|---|
| Return on Assets | -16.37% |
| Return on Invested Capital | -90.54% |
Valuation & Multiples
| P/E Ratio | -20.07 |
|---|---|
| PEG | 5.54 |
| Price to Sales | - |
| Price to Book Ratio | 86.18 |
| Enterprise Value to Revenue | 288.24 |
| Enterprise Value to EBIT | -19.8 |
| Enterprise Value to Net Income | -83 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 2.87 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Reata Pharmaceuticals Inc
CEO: J. Warren Huff